Title : Bladder cancer selective chemotherapy with potent NQO1 substrate co-loaded prodrug nanoparticles.

Pub. Date : 2022 May 31

PMID : 35618186






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Herein, based on the statistically different NQO1 expression between cancerous and normal bladder tissues, the reactive oxygen species (ROS) activatable epirubicin prodrug and highly potent NQO1 substrate, KP372-1, was co-delivered using a GSH-responsive mucoadhesive nanocarrier. Epirubicin NAD(P)H quinone dehydrogenase 1 Homo sapiens
2 After endocytosis, epirubicin could be promptly activated by the NQO1-dependent ROS production caused by KP372-1, thus specifically inhibiting the proliferation of bladder cancer cells. Epirubicin NAD(P)H quinone dehydrogenase 1 Homo sapiens